Company intelligence / Profile preview

Shanghai Changhai Biotechnology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Shanghai Changhai Biotechnology is a Chinese biotechnology company focused on the research and development of innovative therapies for metabolic diseases. The company specializes in the design and optimization of multi-target agonists, particularly focusing on the incretin system including GLP-1, GIP, and Glucagon receptors. Their primary goal is to develop next-generation treatments for type 2 diabetes, obesity, and related metabolic disorders. By leveraging advanced peptide and small molecule chemistry, the company aims to provide more effective and convenient therapeutic options for patients globally.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Changhai Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Changhai Biotechnology.

Explore the full profile